Past work has shown that the CD74:MIF ratio in the circulation can distinguish clinical subtypes of disease or disease progression in autoimmune hepatitis when compared with primary biliary cirrhosis, and work by Ekmekcioglu et al. has shown that CD74:MIF has the potential to prognosticate clinical outcomes in patients with melanoma [17, 33]. The gene discussed is CD74; the disease is melanoma.